Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review.
- Author:
Joon Oh PARK
1
;
Do Youn OH
;
Chiun HSU
;
Jen Shi CHEN
;
Li Tzong CHEN
;
Mauro ORLANDO
;
Jong Seok KIM
;
Ho Yeong LIM
Author Information
- Publication Type:Meta-Analysis ; Review
- Keywords: Biliary tract neoplasms; Cholangiocarcinoma; Cisplatin; Gallbladder neoplasms; Gemcitabine
- MeSH: Appointments and Schedules; Biliary Tract Neoplasms*; Cholangiocarcinoma; Cisplatin*; Congresses as Topic; Drug Therapy; Gallbladder Neoplasms; Humans; Incidence; Population Characteristics
- From:Cancer Research and Treatment 2015;47(3):343-361
- CountryRepublic of Korea
- Language:English
- Abstract: Evidence suggests that combined gemcitabine-cisplatin chemotherapy extends survival in patients with advanced biliary tract cancer (BTC). We conducted a systematic review in order to collate this evidence and assess whether gemcitabine-cisplatin efficacy is influenced by primary tumor site, disease stage, or geographic region, and whether associated toxicities are related to regimen. MEDLINE (1946-search date), EMBASE (1966-search date), ClinicalTrials. gov (2008-search date), and abstracts from major oncology conferences (2009- search date) were searched (5 Dec 2013) using terms for BTC, gemcitabine, and cisplatin. All study types reporting efficacy (survival, response rates) or safety (toxicities) outcomes of gemcitabine-cisplatin in BTC were eligible for inclusion; efficacy data were extracted from prospective studies only. Evidence retrieved from one meta-analysis (abstract), four randomized controlled trials, 12 nonrandomized prospective studies, and three retrospective studies supported the efficacy and safety of gemcitabine-cisplatin for BTC. Median overall survival ranged from 4.6 to 11.7 months, and response rate ranged from 17.1% to 36.6%. Toxicities were generally acceptable and manageable. Heterogeneity in study designs and data collected prevented formal meta-analysis, however exploratory assessments suggested that efficacy did not vary with primary tumor site (gallbladder vs. others), disease stage (metastatic vs. locally advanced), or geographic origin (Asia vs. other). Incidence of grade 3/4 toxicities was not related to gemcitabine dose or cisplatin frequency. Despite individual variation in study designs, the evidence presented suggests that gemcitabine-cisplatin is effective in patients from a diverse range of countries and with heterogeneous disease characteristics. No substantial differences in toxicity were observed among the different dosing schedules of gemcitabine and cisplatin.
